Kantipur Pharmaceuticals Lab has received approval from the Securities Board of Nepal (SEBON) to issue an initial public offering (IPO), clearing the decisive regulatory hurdle for the veterinary pharmaceutical manufacturer to raise funds from the public and list its shares on the Nepali stock market. Under the approved plan, the company will float 1.7 million shares worth Rs 170 million to general investors at a face value of Rs 100 per unit. The issue amounts to 21.25 percent of the company's paid-up capital, and Muktinath Capital has been appointed as the issue and sales manager for the offering.

Offering Structure and Regulatory Clearance

The approved IPO will see Kantipur Pharmaceuticals Lab offer 1.7 million units of ordinary shares at a par value of Rs 100 each, translating into a total issue size of Rs 170 million. The key details of the offering are as follows:

  • Total shares on offer: 1.7 million units
  • Face value: Rs 100 per share
  • Total issue amount: Rs 170 million
  • Share of paid-up capital: 21.25 percent
  • Issue and sales manager: Muktinath Capital

Based on the issue size and the stated ratio, the corresponding paid-up capital works out to Rs 800 million, a figure that will be relevant for investors assessing the company's scale ahead of its market debut.

SEBON's clearance is the mandatory step every company in Nepal must pass before it can collect money from the general public through a share issue. Before granting permission, the regulator examines the issuer's application, financial statements and disclosure documents to ensure that prospective investors receive accurate and complete information about the company and the offering. With that approval now in hand, Kantipur Pharmaceuticals Lab moves from the preparation stage into the final phase of the public issue process.

The issue also carries direct financial implications for the company. Because the shares are being offered at their face value, a successful subscription will add Rs 170 million to the company's equity base as it transitions from a privately held business into a publicly listed entity.

Muktinath Capital to Manage the Issue

Muktinath Capital will oversee the offering in its capacity as the issue and sales manager. In a Nepali IPO, the issue manager is responsible for preparing the offer documents, marketing the issue to investors, collecting applications and coordinating the allotment process once the subscription closes. The firm effectively serves as the operational bridge between the issuing company, the regulator and the investing public throughout the issue period.

With SEBON's approval secured, the company and the issue manager are expected to announce the opening and closing dates of the subscription through formal notices in due course. Nepali investors conventionally subscribe to IPOs through the C-ASBA system, which links their bank accounts to the application, while those holding Demat accounts can apply online through the Mero Share platform. Once applications are collected and the allotment is completed, the shares are credited directly to successful applicants' Demat accounts in preparation for trading.

A Niche Manufacturer in Animal Health

Kantipur Pharmaceuticals Lab operates in the veterinary pharmaceutical segment, producing veterinary medicines, animal nutrition products and feed additives. This positions the company within Nepal's domestic manufacturing sector, serving the animal health and livestock input market with a product range distinct from general consumer goods.

The company's product lines tie it closely to the country's agricultural economy. Veterinary medicines and feed additives are core inputs for livestock and poultry farming, which support a large share of rural households and supply the dairy, meat and egg production that reaches consumers across the country. Demand for such products is driven by the scale of the farming sector, giving the company a market niche that is clearly defined within the broader pharmaceutical and agri-input industries.

Its arrival on the market also adds to the diversity of Nepal's stock exchange, where the listed universe has traditionally been dominated by commercial banks, insurance companies, hydropower developers and microfinance institutions. Manufacturing companies make up a comparatively small portion of listed firms, so the entry of a veterinary pharmaceutical producer offers investors exposure to a segment of the economy that has been underrepresented on the secondary market.

What Comes Next for the Issue and Its Investors

The SEBON approval formally opens the door for the IPO to proceed, but several steps remain before the shares begin trading. The company and Muktinath Capital will publish the offer schedule, including the dates on which applications open and close, along with the minimum and maximum number of shares that different categories of applicants can subscribe to. If the issue is oversubscribed, allotment will be carried out through a lottery among retail applicants, as is standard practice in Nepal's retail-heavy IPO market.

Following the allotment, the shares will be listed on the Nepal Stock Exchange (NEPSE), after which they can be bought and sold on the secondary market. Listing will also bring the company under the disclosure regime that applies to all listed entities, requiring it to publish periodic financial results and inform shareholders of material developments affecting its business.

For Kantipur Pharmaceuticals Lab, the IPO marks a shift from private ownership toward public accountability. The Rs 170 million raised at face value will expand its capital base, while the governance and disclosure obligations that accompany a public listing are expected to bring greater transparency to its operations. For investors, the issue presents an opportunity to subscribe to a manufacturing-sector company at par value ahead of its stock market debut, with the company's performance in the veterinary medicines, animal nutrition and feed additive segments set to shape how the stock is received once trading begins.